Chardan Capital Raises Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $115.00

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price objective boosted by research analysts at Chardan Capital from $90.00 to $115.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target points to a potential upside of 32.52% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Stifel Nicolaus assumed coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They set a “buy” rating and a $98.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Sanford C. Bernstein increased their target price on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Leerink Partners raised their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 17th. Finally, Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $78.00 to $100.00 in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $93.83.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock opened at $86.78 on Wednesday. The firm has a market cap of $12.22 billion, a P/E ratio of -40.36 and a beta of 1.26. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. Arrowhead Pharmaceuticals has a 1-year low of $15.01 and a 1-year high of $95.49. The firm has a fifty day moving average of $77.76 and a two-hundred day moving average of $69.86.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.17. The business had revenue of $73.74 million for the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company’s quarterly revenue was down 86.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.75 earnings per share. As a group, research analysts anticipate that Arrowhead Pharmaceuticals will post -3.09 earnings per share for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director directly owned 52,012 shares in the company, valued at $3,998,682.56. This represents a 5.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Versant Capital Management Inc increased its holdings in shares of Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 248 shares during the period. Carolina Wealth Advisors LLC boosted its stake in Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 154 shares during the period. Tsfg LLC bought a new position in Arrowhead Pharmaceuticals in the 4th quarter worth about $25,000. Optiver Holding B.V. grew its position in Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares during the last quarter. Finally, First Horizon Corp acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Key Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported topline Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran, with both studies meeting the primary endpoint of triglyceride reduction versus placebo; the drug also showed meaningful reductions in acute pancreatitis risk, which investors view as a major de-risking event. Article Title
• Positive Sentiment: Analysts responded favorably to the data, with Piper Sandler reaffirming an overweight rating and raising its price target to $126, and Morgan Stanley lifting its target to $120, reinforcing expectations for further upside if commercialization progresses. Article Title
• Positive Sentiment: Coverage highlighted Arrowhead’s stock move to a new 52-week high and described the plozasiran win as a validation of the company’s late-stage pipeline, with some commentary suggesting broader FDA approval and expanded commercialization potential. Article Title
• Neutral Sentiment: Additional reports noted that Arrowhead’s ARO-033 first-in-human trial showed early safety progress, which is constructive for the pipeline but less immediately important than the plozasiran catalyst. Article Title
• Negative Sentiment: No major negative company-specific news was provided in the recent items, though one market note flagged that the stock’s valuation has run up sharply, which could make further gains more dependent on execution and regulatory follow-through. Article Title

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.